This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (6)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders, Other  • Alert me on articles by topic

Balancing Clinical Benefit and Possible Risks

Arch Dermatol. 2006;142:633-637.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

This editorial has been written at the request of the National Eczema Association for Science and Education (NEASE), San Rafael, Calif. The purpose is to provide an objective, independent view of the evidence surrounding the effectiveness and possible adverse effects of topical calcineurin inhibitors (TCIs) in response to the recent US Food and Drug Administration (FDA) concerns.¹ This editorial is meant for patients with atopic dermatitis (AD) and their health care providers.

Patients with AD often experience chronic unrelieved itching, broken and bleeding skin leading to insomnia, decreased productivity, and low self-esteem. The mainstay of therapy is to keep the associated dry skin moisturized using emollients, to reduce skin inflammation using topical steroids over many years, and to treat superimposed infection. In December 2000, the FDA approved tacrolimus ointment (Protopic; Astellas Pharma US Inc, Deerfield, Ill), a nonsteroid topical agent for use in AD. A year later, in December 2001, . . . [Full Text of this Article]

SYSTEMIC ADVERSE EFFECTS OF TOPICAL CALCINEURIN INHIBITORS


MALIGNANCY IN HUMANS

PHASE 4 STUDIES UPDATE

PRESCRIBING PATTERNS

FIRST-LINE THERAPY

CONTINUOUS THERAPY TO PREVENT DISEASE WORSENING

USE IN CHILDREN YOUNGER THAN 2 YEARS

THE BLACK BOX WARNING

SUMMARY AND LESSONS FOR THE FUTURE

AUTHOR INFORMATION
Abrar A. Qureshi, MD, MPH; Michael A. Fischer, MD, MS

RELATED LETTERS

Topical Calcineurin Inhibitors Labeling: Putting the "Box" in Perspective
Robert S. Stern
Arch Dermatol. 2006;142(9):1233-1235.
EXTRACT | FULL TEXT  

Topical Calcineurin Inhibitors Revisited
Abrar Qureshi and Michael A. Fischer
Arch Dermatol. 2007;143(4):545-546.
EXTRACT | FULL TEXT  

RELATED ARTICLES

National Eczema Association and Topical Calcineurin Inhibitor Labeling
Kevin Cooper
Arch Dermatol. 2007;143(4):546.
EXTRACT | FULL TEXT  

Successful Treatment of Severe Atopic Dermatitis in a Child and an Adult With the T-Cell Modulator Efalizumab
Jeffrey M. Weinberg and Elaine C. Siegfried
Arch Dermatol. 2006;142(5):555-558.
EXTRACT | FULL TEXT  

Development of Atopic Dermatitis During the First 3 Years of Life: The Copenhagen Prospective Study on Asthma in Childhood Cohort Study in High-Risk Children
Liselotte Brydensholt Halkjær, Lotte Loland, Frederik F. Buchvald, Tove Agner, Lone Skov, Matthew Strand, and Hans Bisgaard
Arch Dermatol. 2006;142(5):561-566.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Atopic Dermatitis in Children in the United States, 1997 2004: Visit Trends, Patient and Provider Characteristics, and Prescribing Patterns
Horii et al.
Pediatrics 2007;120:e527-e534.
ABSTRACT | FULL TEXT  

Topical Calcineurin Inhibitors Revisited
Qureshi and Fischer
Arch Dermatol 2007;143:545-546.
FULL TEXT  

National Eczema Association and Topical Calcineurin Inhibitor Labeling
Cooper
Arch Dermatol 2007;143:546-546.
FULL TEXT  

Topical calcineurin inhibitors labeling: putting the "box" in perspective.
Stern
Arch Dermatol 2006;142:1233-1235.
FULL TEXT